These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 29740210)

  • 21. Combined treatment with immunoadsorption and rituximab leads to fast and prolonged clinical remission in difficult-to-treat pemphigus vulgaris.
    Behzad M; Möbs C; Kneisel A; Möller M; Hoyer J; Hertl M; Eming R
    Br J Dermatol; 2012 Apr; 166(4):844-52. PubMed ID: 22092243
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of pemphigus vulgaris: current and emerging options.
    Yeh SW; Sami N; Ahmed RA
    Am J Clin Dermatol; 2005; 6(5):327-42. PubMed ID: 16252932
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment outcomes in a cohort of patients with mucosal-predominant pemphigus vulgaris.
    Ojaimi S; O'Connor K; Lin MW; Schifter M; Fulcher DA
    Intern Med J; 2015 Mar; 45(3):284-92. PubMed ID: 25534017
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mycophenolate mofetil and enteric-coated mycophenolate sodium in the treatment of pemphigus vulgaris and pemphigus foliaceus.
    Doukaki S; Platamone A; Alaimo R; Bongiorno MR
    J Dermatolog Treat; 2015 Feb; 26(1):67-72. PubMed ID: 24521072
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of pemphigus.
    Beissert S; Werfel T; Frieling U; Böhm M; Sticherling M; Stadler R; Zillikens D; Rzany B; Hunzelmann N; Meurer M; Gollnick H; Ruzicka T; Pillekamp H; Junghans V; Luger TA
    Arch Dermatol; 2006 Nov; 142(11):1447-54. PubMed ID: 17116835
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sixteen-year history of rituximab therapy for 1085 pemphigus vulgaris patients: A systematic review.
    Tavakolpour S; Mahmoudi H; Balighi K; Abedini R; Daneshpazhooh M
    Int Immunopharmacol; 2018 Jan; 54():131-138. PubMed ID: 29132070
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term prognosis of pemphigus in Korea: retrospective analysis of 199 patients.
    Kim MR; Kim HC; Kim SC
    Dermatology; 2011; 223(2):182-8. PubMed ID: 22025028
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Analysis of current data on the use of intravenous immunoglobulins in management of pemphigus vulgaris.
    Engineer L; Bhol KC; Ahmed AR
    J Am Acad Dermatol; 2000 Dec; 43(6):1049-57. PubMed ID: 11100022
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Current treatment of autoimmune blistering diseases.
    Kasperkiewicz M; Schmidt E
    Curr Drug Discov Technol; 2009 Dec; 6(4):270-80. PubMed ID: 20025595
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment strategies for pemphigus vulgaris in Japan.
    Hashimoto T
    Expert Opin Pharmacother; 2008 Jun; 9(9):1519-30. PubMed ID: 18518782
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Infective endocarditis in two patients with pemphigus vulgaris under multiagent immunosuppressive drug therapy: A rare entity to remember in the differential diagnosis of fever of unknown origin.
    Küçükoğlu R; Kılıç S; Sun GP
    Dermatol Ther; 2019 May; 32(3):e12860. PubMed ID: 30758911
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Demographic Attributes, Clinical Features, and Optimal Management of 143 Patients with Pemphigus: A Retrospective Observational Study from a Tertiary Care Center of India.
    Mahajan VK; Mehta KS; Sharma J; Kumar P; Chauhan PS; Singh R; Manvi S; Vashist S; Sharma A; Sharma AL
    Indian Dermatol Online J; 2022; 13(2):207-215. PubMed ID: 35287415
    [TBL] [Abstract][Full Text] [Related]  

  • 33. First line treatment of pemphigus vulgaris with a novel protocol in patients with contraindications to systemic corticosteroids and immunosuppressive agents: Preliminary retrospective study with a seven year follow-up.
    Ahmed AR; Nguyen T; Kaveri S; Spigelman ZS
    Int Immunopharmacol; 2016 May; 34():25-31. PubMed ID: 26919279
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rituximab in refractory autoimmune bullous diseases.
    Schmidt E; Hunzelmann N; Zillikens D; Bröcker EB; Goebeler M
    Clin Exp Dermatol; 2006 Jul; 31(4):503-8. PubMed ID: 16716150
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Life-threatening bullous dermatoses: Pemphigus vulgaris.
    Ruocco E; Baroni A; Wolf R; Ruocco V
    Clin Dermatol; 2005; 23(3):223-6. PubMed ID: 15896536
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunoadsorption in the treatment of pemphigus.
    Mlynek A; Meurer M
    Atheroscler Suppl; 2009 Dec; 10(5):107-9. PubMed ID: 20129386
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Current therapy of pemphigus vulgaris.
    Fellner MJ; Sapadin AN
    Mt Sinai J Med; 2001; 68(4-5):268-78. PubMed ID: 11514914
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adjuvant drugs in autoimmune bullous diseases, efficacy versus safety: Facts and controversies.
    Schiavo AL; Puca RV; Ruocco V; Ruocco E
    Clin Dermatol; 2010; 28(3):337-43. PubMed ID: 20541689
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Improved protocol for treatment of pemphigus vulgaris with protein A immunoadsorption.
    Shimanovich I; Herzog S; Schmidt E; Opitz A; Klinker E; Bröcker EB; Goebeler M; Zillikens D
    Clin Exp Dermatol; 2006 Nov; 31(6):768-74. PubMed ID: 16824051
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pemphigus Vulgaris Aggravated: Rifampicin Found at the Scene of the Crime.
    Hu L; Sun Y; Gao Z; Wang P
    Cutis; 2022 May; 109(5):E19-E21. PubMed ID: 35856757
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.